$3.00
-0.03-0.99%
Last update: Nov 9, 8:24 AM
SAB Biotherapeutics Inc
SABSNASDAQ
The average analyst price target for SAB Biotherapeutics is $10.86, 262.0% above the current price. Of 12 analysts, 12 rate it Buy. Targets range from $6 to $16. The latest change came on Jun 24, 2026, when Barclays initiated coverage of SAB Biotherapeutics with an Overweight rating and a $13 price target.
Price Target Range — 11 Quarters
Analyst Consensus — 12 Analysts
Rating Trend — Last 9 Months
